Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-κB and NLRP3 inflammasome activation

CNS Neuroscience and Therapeutics

Volumn 19, Issue 4, 2013, Pages 262-268

  Shi, Jian Quan ^a   Zhang, Chu Chu ^b   Sun, Xiu Lan ^b   Cheng, Xin Xin ^b   Wang, Jiang Bo ^b   Zhang, Ying Dong ^a   Xu, Jun ^b   Zou, Hai Qiang ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

Amyloid beta; Artemisinin; BACE1; NALP3 inflammasome; NF B

Indexed keywords

AMYLOID BETA PROTEIN; ARTEMISININ; BETA SECRETASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFECT; IN VIVO STUDY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIMALARIALS; ARTEMISININS; CARRIER PROTEINS; INFLAMMASOMES; INFLAMMATION; MICE; MICE, TRANSGENIC; NEURONS; NF-KAPPA B; PLAQUE, AMYLOID; PRESENILIN-1; UP-REGULATION;

EID: 84875611419     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12066     Document Type: Article

References (45)

1. Cummings JL, Cole G. Alzheimer disease. JAMA 2002;287:2335-2338.
2. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011;34:185-204.
3. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2:a006346.
4. He P, Zhong Z, Lindholm K, et al. Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 2007;178:829-841.
5. Lim JE, Kou J, Song M, et al. MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease. Am J Pathol 2011;179:1095-1103.
6. Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel UL. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J Alzheimers Dis 2009;16:809-821.
7. Bourne KZ, Ferrari DC, Lange-Dohna C, Rossner S, Wood TG, Perez-Polo JR. Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007;85:1194-1204.
8. Chen CH, Zhou W, Liu S, et al. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol 2012;15:77-90.
9. Paris D, Patel N, Quadros A, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett 2007;415:11-16.
10. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009;183:787-791.
11. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008;9:857-865.
12. Salminen A, Ojala J, Suuronen T, Kaarniranta K, Kauppinen A. Amyloid-beta oligomers set fire to inflammasomes and induce Alzheimer's pathology. J Cell Mol Med 2008;12:2255-2262.
13. Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: From a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol 2012;2012:247597.
14. Xiong Z, Sun G, Zhu C, et al. Artemisinin, an anti-malarial agent, inhibits rat cardiac hypertrophy via inhibition of NF-κB signaling. Eur J Pharmacol 2010;649:277-284.
15. Wang Y, Huang Z, Wang L, et al. The anti-malarial artemisinin inhibits pro-inflammatory cytokines via the NF-κB canonical signaling pathway in PMA-induced THP-1 monocytes. Int J Mol Med 2011;27:233-241.
16. Zhu C, Xiong Z, Chen X, et al. Artemisinin attenuates lipopolysaccharide-stimulated proinflammatory responses by inhibiting NF-κB pathway in microglia cells. PLoS One 2012;7:e35125.
17. Gu Y, Wang X, Wang X, et al. Artemisinin attenuates post-infarct myocardial remodeling by down-regulating the NF-κB pathway. Tohoku J Exp Med 2012;227:161-170.
18. Wu X, Zhang W, Shi X, An P, Sun W, Wang Z. Therapeutic effect of artemisinin on lupus nephritis mice and its mechanisms. Acta Biochim Biophys Sin (Shanghai) 2010;42:916-923.
19. Wang Z, Qiu J, Guo TB, et al. Anti-inflammatory properties and regulatory mechanism of a novel derivative of artemisinin in experimental autoimmune encephalomyelitis. J Immunol 2007;179:5958-5965.
20. Shi JQ, Shen W, Chen J, et al. Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011;1368:239-247.
21. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004;13:159-170.
22. Malm T, Koistinaho J, Kanninen K. Utilization of APPswe/PS1dE9 transgenic mice in research of Alzheimer's disease: Focus on gene therapy and cell-based therapy applications. Int J Alzheimers Dis 2011;2011:517160.
23. Gabbita SP, Srivastava MK, Eslami P, et al. Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2012;9:99.
24. Sehgal N, Gupta A, Valli RK, et al. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci USA 2012;109:3510-3515.
25. Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008;205:2781-2789.
26. Robert A, Benoit-Vical F, Claparols C, et al. The antimalarial drug artemisinin alkylates heme in infected mice. Proc Natl Acad Sci USA 2005;102:13676-13680.
27. Reale M, Kamal MA, Velluto L, Gambi D, Di Nicola M, Greig NH. Relationship between inflammatory mediators, Aβ levels and ApoE genotype in Alzheimer disease. Curr Alzheimer Res 2012;9:447-457.
28. int'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001;345:1515-1521.
29. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 2002;59:880-886.
30. Bonaiuto C, McDonald PP, Rossi F, Cassatella MA. Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia. J Neuroimmunol 1997;77:51-56.
31. Kawamoto EM, Lepsch LB, Boaventura MF, et al. Amyloid beta-peptide activates nuclear factor-kappaB through an N-methyl-D-aspartate signaling pathway in cultured cerebellar cells. J Neurosci Res 2008;86:845-860.
32. Yi H, Lee SJ, Lee J, et al. Sphingosylphosphorylcholine attenuated β-amyloid production by reducing BACE1 expression and catalysis in PC12 cells. Neurochem Res 2011;36:2083-2890.
33. Paris D, Beaulieu-Abdelahad D, Bachmeier C, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol 2011;670:384-391.
34. Choi DY, Lee JW, Lin G, et al. Obovatol attenuates LPS-induced memory impairments in mice via inhibition of NF-κB signaling pathway. Neurochem Int 2012;60:68-77.
35. Lee YJ, Choi DY, Choi IS, et al. Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation 2012;9:35.
36. Choi DY, Lee JW, Peng J, et al. Obovatol improves cognitive functions in animal models for Alzheimer's disease. J Neurochem 2012;120:1048-1059.
37. Chami L, Buggia-Prévot V, Duplan E, et al. Nuclear factor-κB regulates βAPP and β- and γ-secretases differently at physiological and supraphysiological Aβ concentrations. J Biol Chem 2012;287:24573-24584.
38. Jiang LY, Tang SS, Wang XY, et al. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of Type 2 diabetes mellitus. CNS Neurosci Ther 2012;18:659-666.
39. Paris D, Ganey NJ, Laporte V, et al. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2010;7:17.
40. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013;493:674-678.
41. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010;330:1774.
42. Deane R, Bell RD, Sagare A, Zlokovic BV. Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 2009;8:16-30.
43. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004;35(11 Suppl 1):2628-2631.
44. Guglielmotto M, Aragno M, Tamagno E, et al. AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation. Neurobiol Aging 2012;33:196.e13-27.
45. Kim H, Park BS, Lee KG, et al. Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 2005;53:8537-8541.